In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram

Psychopharmacology

Volumn 188, Issue 3, 2006, Pages 263-272

  Klein, N ^a   Sacher, J ^a   Geiss Granadia, T ^a   Attarbaschi, T ^a   Mossaheb, N ^a   Lanzenberger, R ^a   Potzi C ^a   Holik, A ^a   Spindelegger, C ^a   Asenbaum, S ^a   Dudczak, R ^a   Tauscher, J ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Citalopram; Escitalopram; Serotonin reuptake transporter; SPECT; SSRI

Indexed keywords

2 ((2 ((DIMETHYLAMINO)METHYL)PHENYL)THIO) 5 IODOPHENYLAMINE I 125; CITALOPRAM; ESCITALOPRAM; PLACEBO; RADIOLIGAND; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; HYPOSALIVATION; IN VIVO STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MESENCEPHALON; NAUSEA; NEUROIMAGING; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; RESTLESSNESS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE;

ADMINISTRATION, ORAL; ADULT; AKATHISIA, DRUG-INDUCED; AREA UNDER CURVE; CEREBELLUM; CINANSERIN; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IODINE RADIOISOTOPES; MALE; MESENCEPHALON; METABOLIC CLEARANCE RATE; NAUSEA; PROTEIN BINDING; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS; STEREOISOMERISM; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XEROSTOMIA;

EID: 33748666835     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0486-0     Document Type: Article

References (47)

1. Acton PD, Choi SR, Hou C, Plossl K, Kung HF (2001) Quantification of serotonin transporters in nonhuman primates using [123I] ADAM and SPECT. J Nucl Med 42(10):1556-1562
2. Alexopoulos GS, Privitera W, Ventura D, Bose A, Lenz SM, Wang Q (2004) Fixed dose of escitalopram (10 mg/day) and a flexible dosing regime of sertraline (50-200 mg/day) in a randomized, double-blind comparison in depressed patients. World J Biol Psychiatry 5(Suppl 1):97
3. Backstrom I, Bergstrom M, Marcusson J (1989) High affinity [3H] paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 486(2):261-268
4. Baumann P, Larsen F (1995) The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287-295
5. Catafau AM, Perez V, Penengo MM, Bullich S, Danus M, Puigdemont D, Pascual JC, Corripio I, Llop J, Perich J, Alvarez E (2005) SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med 46(8):1301-1309
6. Chen F, Larsen MB, Sanchez C, Wiborg O (2003) The S-enantiomer of citalopram increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 12:S217
7. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, Acton PD, Kung HF (2000) Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 38(4):403-412
8. Erlandsson KT, Sivananthan D Lui, Spezzi A, Townsend CE, Mu S, Lucas R, Warrington S, Ell PJ (2005) Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging 32(11):1329-1336
9. Frey R, Schreinzer D, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S (2000) Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 10(2):133-142
10. Frokjaer VG, Pinborg LH, Madsen H, Knudsen GM (2004) Evaluation of the serotonin transporter ligand [123I]ADAM for SPECT studies in humans. Neuroimage 22(Suppl 2):T176
11. Gorman JM, Kent JM (1999) SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60(Suppl 4):33-38 (Discussion 39)
12. Gorman JM, Korotzer A, Su G (2002) Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7(4 Suppl):40-44
13. Kasper S (2004) Unique mechanism of action for escitalopram: does it hold the promise? Int J Psychiatry Clin Pract 8(Suppl 1):15-18
14. Kasper S, Heiden A (1995) Do SSRIs differ in their antidepressant efficacy? Hum Psychopharmacol 10:163-171
15. Kasper S, Vieira A, Schmidt R, Richter P (1990) Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment. Pharmacopsychiatry 23(2): 76-84
16. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brucke T (2002) Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J Biol Psychiatry 3(3):133-146
17. Kasper S, Spadone C, Verpillat P, Angst J (2006) Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 21(2):105-110
18. Kauppinen TA, Bergstrom KA, Heikman P, Hiltunen J, Ahonen AK (2003) Biodistribution and radiation dosimetry of [123I]ADAM in healthy human subjects: preliminary results. Eur J Nucl Med Mol Imaging 30(1):132-136
19. Klein N, Sacher J, Mossaheb N, Asenbaum S, Pötzi C, Dobrozemsky G, Dudczak R, Kasper S, Tauscher J (2004) Quantification of serotonin transporters with [123I]ADAM and SPECT in healthy human subjects: preliminary data on tracer kinetics. Biol Psychiatry 55:S212
20. Kugelberg F, Carlsson CB, Ahlner J, Bengtsson F (2003) Stereo-selective single-dose kinetics of citalopram and its metabolites in rats. Chirality 15(7):622-629
21. Larsen F, Priskorn M, Overo KF (2001) Lack of citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol 41(3):340-346
22. Larsen AK, Brennum LT, Egebjerg J, Sanchez C, Halldin C, Andersen PH (2004) Selectivity of 3H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol 141(6):1015-1023
23. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL et al (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13(4):295-309
24. Lepola UM, Loft H (2003) Reines EH Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211-217
25. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1-100
26. Llorca PM, Azorin JM, Despiegel N, Verpillat P (2005) Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59(3):268-275
27. Malling D, Poulsen MN, Sogaard B (2005) The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol 60(3):287-290
28. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S (2001) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158(11):1843-1849
29. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S Links P (2003) Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 160(1):90-99
30. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826-835
31. Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M (2001) Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88(5):282-286
32. Moore N, Verdoux H, Fantino B (2005) Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20(3):131-137
33. Mork A, Kreilgaard M, Sanchez C (2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45(2):167-173
34. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Herscovitch P, Charney DS, Drevets WC (2004) Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24(3):589-591
35. Oya S, Choi SR, Hou, Mu M, Kung MP, Acton PD, Siciliano M Kung HF (2000) 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 27(3):249-254
36. Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brucke T (1995) beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 100(3):247-256
37. Rochat B, Baumann P, Audus KL (1999) Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831(1-2):229-236
38. Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Pötzi C, Attarbaschi T, Lanzenberger R, Dudczak R, Kasper S, Tauscher J (2006) [123I]ADAM: a novel SPECT ligand for quantification of serotonin transporters in humans. Int J Neuropsychopharmacology (in press)
39. Sanchez C, Kreilgaard M (2004) R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77(2):391-398
40. Sanchez C, Gruca P, Bien E, Papp M (2003a) R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 75(4):903-907
41. Sanchez C, Gruca P, Papp M (2003b) R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14(5-6):465-470
42. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C (2004) Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174(2):163-176
43. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9(7):686-692
44. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M Ebert B (2004) R-citalopram functionally antagonises scitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142(1):172-180
45. Tauscher J, Pirker W, de Zwaan M, Asenbaum S, Brucke T, Kasper S (1999) In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol 9(1-2):177-179
46. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7(3):317-321
47. Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Asenbaum S, Vitouch O, Tauscher J, Hilger E, Stastny J, Brucke T, Kasper S (2000) [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 47(6):482-489